<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919787</url>
  </required_header>
  <id_info>
    <org_study_id>NorPACT-1</org_study_id>
    <secondary_id>2015-001635-21</secondary_id>
    <nct_id>NCT02919787</nct_id>
  </id_info>
  <brief_title>Norwegian Pancreatic Cancer Trial (NorPACT) - 1</brief_title>
  <official_title>Norwegian Pancreatic Cancer Trial (NorPACT) - 1: Norwegian Multicentre Un-blinded Phase III Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the additional effect of adding chemotherapy prior to resection of a
      pancreatic head malignancy. The patients will be randomized into two groups; surgery first
      (control group) and neoadjuvant chemotherapy (intervention). Primary endpoint is overall
      survival after resection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is the fourth leading cause of cancer-related deaths in Europe and the
      United States. Surgical resection remains the only potentially curative treatment. However,
      the median survival of patients undergoing pancreatic resection alone is 16-23 months. The
      administration of adjuvant chemotherapy leads to an improvement in overall survival. Thus,
      completion of multimodality treatment (MMT) is the ideal goal and standard of care for
      treatment of pancreatic ductal adenocarcinoma (PDAC).

      Currently, the surgery-first (SF) strategy is the most universally accepted approach to
      resectable PDAC (and is the standard of care in Norway), but the optimal sequence of surgery
      and chemotherapy remains unclear.

      The purpose of this study is to further investigate the additional efficacy of neoadjuvant
      chemotherapy to the standard treatment for resectable cancer of the pancreatic head (surgery
      followed by adjuvant chemotherapy).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival one year after resection</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival at one year following commencement of allocated treatment for those who ultimately undergo resection (ie: only resected patients analyzed).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival after date of randomization (intention to treat)</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of neoadjuvant and adjuvant chemotherapy (Common Terminology Criteria for Adverse Events, grade 3-5, dose reduction, dose delay)</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery and then postoperative adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Adjuvant treatment</description>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Adjuvant treatment</description>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatine</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatic surgery</intervention_name>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resectable adenocarcinoma of the pancreatic head

          -  T1-3, Nx, M0 (UICC 7th version, 2010)

          -  Cytologic or histologic confirmation of adenocarcinoma

          -  Age &gt; 18 year and considered fit for major surgery

          -  Written informed consent

          -  Considered able to receive the study specific chemotherapy

        Exclusion Criteria:

          -  Co-morbidity precluding pancreaticoduodenectomy

          -  Chronic neuropathy ≥ grade 2

          -  WHO performance score &gt; 2 • Granulocyte count &lt; 1500 per cubic millimetre

          -  Platelet count &lt; 100 000 per cubic millimeter

          -  Serum creatinine &gt; 1.5 UNL (upper limit normal range)

          -  Albumin &lt; 2,5 g/dl

          -  Female patients in child bearing age not using adequate contraception, pregnant or
             lactating women • Mental or organic disorders which could interfere with informed
             consent or treatments

          -  Other malignancy within the past 5 years, except non-melanomatous skin or non-invasive
             cervical cancer

          -  Percutaneous tumor biopsy

          -  Any reason why, in the opinion of the investigator, the patient should not participate

          -  Pregnancy

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Svein Dueland, MD, PhD</last_name>
    <phone>22934000</phone>
    <phone_ext>+47</phone_ext>
    <email>svedue@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N- 0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svein Dueland, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Svein Dueland</investigator_full_name>
    <investigator_title>Senior consultant medical oncology</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

